Supplementary Figure 1 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma

Supplementary Figure 1. Survival outcomes of patients with synchronous and metachronous metastatic disease and treatment flows. Overall survival (OS) for patients with synchronous and metachronous metastatic FH-deficient RCC in the overall systemic treatment setting (A), ICI+TKI treatment setting (B), and TKI monotherapy setting (C); (D) Sankey diagram showing systemic treatment flows in patients with metastatic FH-deficient RCC.